Genitourinary Cancers Clinical Trials & Research at Providence Medical Group
Genitourinary (GU) cancers encompass a diverse group of malignancies affecting
the urinary system and the male reproductive organs. This category includes
cancers of the bladder, kidneys, prostate, testicles, and penis. These
cancers vary widely in their biology, prognosis, and treatment options,
making clinical research crucial for improving patient outcomes.
Clinical trials are fundamental to the advancement of GU cancer treatment.
These studies investigate new therapies and interventions, aiming to enhance
the effectiveness and reduce the side effects of existing treatments.
They encompass a wide range of approaches, including novel drug therapies,
immunotherapies, targeted treatments, surgical techniques, and combinations
of these modalities.
Prostate/Endometrial and Pancreatic cancer studies are also included in
these trials.
Pancreatic cancer develops in the pancreatic ductal, acinar, and islet
cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal
(PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers
in the U.S. Risk factors that can be changed include tobacco use, obesity,
and workplace exposure to certain chemicals.
Providence Medical Group is currently enrolling patients for the following
genitourinary cancers clinical trials:
(Currently Suspended)
NRG-GU010 Guidance Study Phase III Randomized Trial of Genomic-Risk Stratified
Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And
Intensification Clinical Trial Evaluation
Treatment agent: Radiotherapy +/- Androgen Deprivation Therapy (ADT)
Physician:
Michael N. Corradetti
Study Coordinator: Beatrice Becker //
beatrice.becker@providence.org // 707-932-5164
Study Resources:
https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / NRG Oncology Clinical Trials
Location: Providence Queen of the Valley Medical Center, Napa, CA
EMD Serono MS201924-0020 (DDriver solid tumors 320)- Metastatic or Locally
Advanced Unresectable solid tumors. Prostate/Endometrial Cancer
Treatment agent: (Open label): M1774, M4076 (orals) + Avelumab (IV)
Physician:
Ian Anderson, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM
inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid
tumors | Cancer Research | American Association for Cancer Research (aacrjournals.org)
Sponsor: IQVIA
Location: Providence Cancer Center, Santa Rosa, CA
NRG-GU009, Parallel Phase III Randomized Trials For High Risk Prostate
Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification
of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*)
Treatment agent: Radiotherapy
Physician:
Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker //
beatrice.becker@providence.org // 707-932-5164
Study Resources:
Study Details | Two Studies for Patients With High Risk Prostate Cancer
Testing Less Intense Treatment for Patients With a Low Gene Risk Score
and Testing a More Intense Treatment for Patients With a High Gene Risk
Score, The PREDICT-RT Trial | ClinicalTrials.gov
Sponsor: NRG Oncology
Location: Providence Queen of the Valley Medical Center, Napa, CA
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab
vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic
Cancer Patients with DNA Damage Repair Defects (SWOG S2001)
Treatment agent: Olaparib +/- Pembrolizumab
Physician:
Yao Yao Pollock, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT04548752
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center, Santa Rosa, CA
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and
Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine
Tumors (SWOG S2104)
Treatment agent: Capecitabine and Temozolimide
Physician:
Yao Yao Pollock, MD
Study Coordinator: Beatrice Becker //
beatrice.becker@providence.org // 707-932-5164
Study Resources:
https://www.clinicaltrials.gov/study/NCT05040360
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center, Santa Rosa, CA
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability,
Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination
with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing
Claudin 18.2 (CLARITY-PanTumour01)